DNMT3B gene amplification was observed in breast cancer cells and was associated with resistance to DNA demethylating drugs, including Decitabine, 5-azacytidine (Vidaza), and SGI-1027 (Simo-Riudalbas et al., 2011). This evidence concerns the gene DNMT3B and breast cancer.